NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 17.46 against a street estimate of 17.26 — a beat of 1.2%.
with an average price target of ₹1,689.59.
CONFIDENT Q1 FY27 delivered 16% revenue growth to INR 9,150 cr with 21% EBITDA margins. Lannett acquisition complete; biosimilar filings imminent; China facility doubled output. Guidance reiterated: double-digit growth, EBITDA >21%, absolute EBITDA >INR 8,000 cr. Q1 FY27 Europe and growth markets driving momentum; US stabilizing post-Lannett. China ramp and backward integration (captive supply) improving margins and reducing third-party dependency. Analysts pressed on Lannett synergies timeline (margins 9+ months), growth markets drivers (all regions, no outlier), and biosimilar Wave 1 positioning (subcutaneous, device combos, subclinical studies by year-end). Management reaffirmed near-term margin upside and strategic differentiation via complex products and CMO/CDMO. 2026-08-06…
Full summary in the app.
| Document | Date |
|---|---|
| Q1 FY27 earnings call AUROBINDO PHARMA LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Consolidated revenues: Rs. 9,150 crores, up 16% year-on-year • Operating EBITDA: Rs. 1 | 2026-08-13 |
| Quarterly results · Q1 FY27 AUROBINDO PHARMA LIMITED – Q1 FY27 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from Operations: INR 9,150 Cr in Q1FY27, up 16.3% YoY (Q1FY26: INR 7 | 2026-08-05 |
| Investor presentation · Q1 FY27 AUROBINDO PHARMA LIMITED – Q1FY27 SUMMARY HEADLINE NUMBERS • Revenue: ₹9,150 Cr (Q1FY27) vs ₹7,868 Cr (Q1FY26) – 16.3% Y-o-Y growth • Operating EBIT | 2026-08-05 |
| Annual report FY2026 AUROBINDO PHARMA LIMITED – FY26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue from Operations: ₹33,653 Cr (6% Y-o-Y growth) • EBITDA: ₹6,8 | 2026-08-03 |
| Q4 FY26 earnings call AUROBINDO PHARMA LIMITED – Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • FY26 Full Year Revenue: ₹33,653 crores (6% YoY growth; 9.5% ex-Revlimid) • FY | 2026-05-27 |
| Investor presentation · Q4 FY26 AUROBINDO PHARMA LIMITED – Q4FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4FY26 Revenue: ₹8,853 crores with 5.6% YoY growth; FY26 full-year revenue ₹33 | 2026-05-21 |
| Quarterly results · Q4 FY26 AUROBINDO PHARMA LIMITED – Q4 FY26 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from Operations (FY26): INR 33,653 Cr, up 6.1% YoY (Q4FY26: INR 8,85 | 2026-05-21 |
| Q3 FY26 earnings call AUROBINDO PHARMA LIMITED - Q3 FY26 SUMMARY --- HEADLINE NUMBERS • Consolidated revenue: Rs. 8,646 crores, up 8.4% year-on-year • EBITDA: Rs. 1,773 | 2026-02-16 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquisition of another business announced Aurobindo Pharma has invested USD 1 million (₹8.3 crore approximately) to subscribe to 10,000 equity shares of A1 Biochem USA Inc, a newly incorporated subsidiary in the USA. This investment | 2026-09-12 |
| Acquires majority ownership control in A1 Biochem Labs entities Aurobindo Pharma Limited has acquired majority ownership control of two companies: A1 Biochem Labs (India) Private Limited operating in India, and A1 Biochem Labs LLC operating in the USA. | 2026-07-23 |
| ANVISA approval received for biosimilars manufacturing facility Gland Pharma's wholly-owned subsidiary CuraTeQ Biologics has received approval from ANVISA (Brazil's health regulator) for its biosimilars manufacturing facility. Biosimilars are lower-cost | 2026-07-21 |
| Completion of Lannett acquisition by subsidiary Intimation of completion of Lannett acquisition by Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. | 2026-06-30 |
| Acquisition announced by pharmaceutical company Aurobindo Pharma Limited has informed the Exchange about Acquisition | 2026-06-25 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aurobindo Pharma Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.